Stock CRNX CRINETICS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Market Closed - Nasdaq
Other stock markets
 01:30:00 26/06/2024 am IST 		5-day change 1st Jan Change
44.87 USD -1.73% Intraday chart for Crinetics Pharmaceuticals, Inc. +1.31% +26.11%
25/06 Crinetics Pharmaceuticals Insider Sold Shares Worth $434,435, According to a Recent SEC Filing MT
04/06 Oppenheimer Raises Price Target on Crinetics Pharmaceuticals to $74 From $55, Maintains Outperform Rating MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
GL
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
GL
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
GL
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
GL
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
GL
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
GL
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
GL
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Crinetics Pharmaceuticals : Topline Results from Paltusotine Phase 3 PATHFNDR-2 Study
PU
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
GL
Crinetics Pharmaceuticals : Presents Data from Phase 2 Study of Paltusotine in Carcinoid Syndrome
PU
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
GL
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GL
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
GL
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRNX Stock
  4. News Crinetics Pharmaceuticals, Inc.
  5. Press Releases